In locally advanced and metastatic disease not suitable for surgery or radiotherapy, responses to chemotherapy and/or Epidermal Growth factor Receptor (EGFR) inhibitors are limited and although anti-Programmed Cell Death 1 (PD1) checkpoint immunotherapy is now considered first line, 50% of individuals fail to respond7 highlighting the need for better treatment modalities. The gene discussed is EGFR; the disease is metastatic neoplasm.